Emcure Pharmaceuticals Ltd. has announced the introduction of India’s first generic version of sucroferric oxyhydroxide for the control of increased serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
The drug will be sold under the brand name Dynulta. Its active component is sucroferric oxyhydroxide, developed indigenously by Emcure. The medicine is currently available now across the country.
The market size of this segment is ₹50 crore. Without disclosing the targeted market share, company executives said their main objective is to make the product available to patients and cater to the requirement of 75% of the patients in three years.
Dynulta will be manufactured at Emcure’s plant at Jammu and will be marketed at less than 70% cost of the innovator brand Vifor Fresenius Medical Care Renal Pharma Ltd., a joint operation between Vifor Pharma and Fresenius Medical care, the providers of dialysis services. It is marketed internationally as Velphoro.
“The incidence of CKD is on the rise in India. Dynulta will provide efficacious and cost-effective remedy for Indian patients,” said Namita Thapar, executive director, Emcure Pharmaceuticals Ltd., in a video conference.
You have reached your limit for free articles this month.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Not convinced? Know why you should pay for news.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath